PT. Daewoong Pharmaceutical Company Indonesia
Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. Daewoong is dedicated to completing the Phase 2 clinical study of this drug by 2025. For more information, visit Daewoong Pharmaceutical's website and LinkedIn page. Media inquiries can be directed to Daewoong's PR at naraesong@daewoong.co.kr.

Contact:
Wework Revenue Tower 26th, Scbd, Jl. Jenderal Sudirman No.52-53, RT.5/RW.3, Senayan, Jakarta, South Jakarta City, Jakarta 12190
Kota Jakarta Utara , Prov. D.K.I. Jakarta
Indonesia
Maaf, sepertinya belum ada lowongan yang tersedia untuk saat ini.
Silakan cek kembali disaat yang lain.
Maaf, sepertinya belum ada panggilan tes yang tersedia untuk saat ini.
Silakan cek kembali disaat yang lain.